The recent development of immunotherapy has advanced the treatment of various cancers. The anti-PD-1 antibody nivolumab was designated by the FDA as a breakthrough therapy in September 2014. Subsequently, the anti-PD-1 antibody pembrolizumab received the same designation. Nivolumab is currently approved as a drug with good efficacy against a range of specific malignancies including malignant melanoma, non-small cell lung cancer, kidney cancer, stomach cancer, Hodgkin's lymphoma, and urothelial carcinoma. In addition, it is being investigated for the treatment of other types of cancer in promising clinical studies. Pembrolizumab was also approved by the FDA for similar indications in addition to the microsatellite instability-high or mismatch repair-deficient solid tumors. Open in a separate window Prof. M.
No takes yet. Share an insight, caveat, or question.
Masatoshi Kudo (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Liver Cancer